A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy

Pharmacogenetics and Genomics

Volumn 22, Issue 4, 2012, Pages 229-235

  Kiyotani, Kazuma ^a   Uno, Satoko ^b   Mushiroda, Taisei ^a   Takahashi, Atsushi ^a   Kubo, Michiaki ^a   Mitsuhata, Naoki ^c   Ina, Shinomi ^d   Kihara, Chikashi ^e   Kimura, Yasutoshi ^e   Yamaue, Hiroki ^d   Hirata, Koichi ^e   Nakamura, Yusuke ^a,b   Zembutsu, Hitoshi ^b  

^a RIKEN   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kure Kyosai Hospital   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

adverse drug reaction; myelosuppression; pancreatic cancer; single nucleotide polymorphism

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; GEMCITABINE;

ADULT; ARTICLE; BILE DUCT CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CHROMOSOME 1P; CHROMOSOME 2Q; CHROMOSOME 3Q; CHROMOSOME 9P; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84859101072     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834e9eba     Document Type: Article

References (33)

1. Cortes-Funes H, Martin C, Abratt R, Lund B. Safety profile ofgemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs 1997; 8:582-587. (Pubitemid 27373437)
2. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ, et al. Gemcitabine and cisplatin inthe treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11:1399-1403.
3. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, et al. Prognostic factors inJapanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38:755-761.
4. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009; 24:800-805.
5. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, et al. Gemcitabine transport inxenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999; 91:1876-1881.
6. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001; 276:2914-2927.
7. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58:4349-4357. (Pubitemid 28450036)
8. Van Rompay AR, Johansson M, Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 2003; 100:119-139. (Pubitemid 37377909)
9. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition ofribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 1990; 38:567-572. (Pubitemid 20356209)
10. Plunkett W, Huang P, Gandhi V. Preclinical characteristics ofgemcitabine. Anticancer Drugs 1995; 6 (Suppl 6):7-13.
11. Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, et al. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 2007; 12:622-630.
12. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics ofgemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25:32-42. (Pubitemid 350003048)
13. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116:5325-5335.
14. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase IIstudies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27:2163-2169.
15. Nakamura Y. The BioBank Japan Project. Clin Adv Hematol Oncol 2007; 5:696-697. (Pubitemid 351699412)
16. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46:471-477. (Pubitemid 32744120)
17. International HapMap Consortium. The International HapMap Project. Nature 2003; 426:789-796.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: atool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575. (Pubitemid 47330214)
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
21. Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 1998; 17:3331-3340. (Pubitemid 29043985)
22. Kimchi A. DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. Biochim Biophys Acta 1998; 1377:F13-F33. (Pubitemid 28207051)
23. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, et al. Overexpression oftranslocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002; 87:569-577. (Pubitemid 34640638)
24. Holleman A, den Boer ML, de Menezes RX, Cheok MH, Cheng C, Kazemier KM, et al. The expression of70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107:769-776. (Pubitemid 43076404)
25. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. Establishment and characterization ofmultidrug-resistant gastric cancer cell lines. Anticancer Res 2010; 30:915-921.
26. Muller T, Engels P, Fozard JR. Subtypes ofthe type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci 1996; 17:294-298. (Pubitemid 26261894)
27. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157:351-370. (Pubitemid 28090521)
28. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, Targretin), aselective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007; 67:4425-4433. (Pubitemid 46815092)
29. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation ofCDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14:1797-1803. (Pubitemid 351469466)
30. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms ofgemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16:320-329.
31. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11:2620-2624. (Pubitemid 40569462)
32. Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, et al. Distribution ofgemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63:121-127.
33. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, et al. Homozygous CDA*3 is amajor cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009; 100:870-873.